PDT Partners LLC Invests $1.26 Million in Phreesia, Inc. $PHR

Key Points

• PDT Partners LLC has invested approximately $1.26 million in Phreesia, acquiring 49,232 shares valued at about $1,258,000, representing 0.08% ownership of the company.
• Phreesia's stock is currently priced at $30.40, with a market cap of $1.81 billion and a twelve-month price range between $17.07 and $32.76.
• Analysts maintain a consensus buy rating for Phreesia, with target prices ranging up to $36.00, indicating growth potential despite a recent 3.4% decline in stock value.

PDT Partners LLC bought a new stake in Phreesia, Inc. (NYSE:PHR - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 49,232 shares of the company's stock, valued at approximately $1,258,000. PDT Partners LLC owned about 0.08% of Phreesia as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also bought and sold shares of PHR. KBC Group NV bought a new position in shares of Phreesia during the first quarter worth approximately $74,000. CWM LLC grew its stake in shares of Phreesia by 994.9% during the first quarter. CWM LLC now owns 4,040 shares of the company's stock worth $103,000 after buying an additional 3,671 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Phreesia by 53.0% during the first quarter. Smartleaf Asset Management LLC now owns 5,267 shares of the company's stock worth $137,000 after purchasing an additional 1,825 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Phreesia by 1,023.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,660 shares of the company's stock worth $142,000 after purchasing an additional 5,156 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in shares of Phreesia by 10,605.7% during the first quarter. GAMMA Investing LLC now owns 5,674 shares of the company's stock worth $145,000 after purchasing an additional 5,621 shares during the period. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Phreesia

In other Phreesia news, Director Lisa Egbuonu-Davis sold 2,802 shares of the firm's stock in a transaction on Thursday, June 26th. The shares were sold at an average price of $27.67, for a total value of $77,531.34. Following the sale, the director owned 22,037 shares of the company's stock, valued at $609,763.79. This trade represents a 11.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP David Linetsky sold 23,729 shares of the firm's stock in a transaction on Friday, June 27th. The stock was sold at an average price of $28.50, for a total transaction of $676,276.50. Following the completion of the sale, the senior vice president directly owned 193,510 shares in the company, valued at approximately $5,515,035. This trade represents a 10.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 109,292 shares of company stock worth $3,295,323 in the last 90 days. Corporate insiders own 5.50% of the company's stock.

Phreesia Stock Performance

Shares of PHR stock traded down $0.30 during trading on Tuesday, reaching $26.48. 463,508 shares of the company's stock traded hands, compared to its average volume of 567,210. The company has a market capitalization of $1.58 billion, a P/E ratio of -63.04 and a beta of 0.72. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.02. The firm's 50-day moving average is $28.31 and its 200 day moving average is $26.50. Phreesia, Inc. has a 1 year low of $17.07 and a 1 year high of $32.76.

Phreesia (NYSE:PHR - Get Free Report) last posted its quarterly earnings data on Thursday, September 4th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.08. The firm had revenue of $117.26 million for the quarter, compared to analysts' expectations of $116.39 million. Phreesia had a negative net margin of 5.35% and a negative return on equity of 9.00%. The business's quarterly revenue was up 14.9% on a year-over-year basis. During the same quarter last year, the company posted ($0.03) EPS. Phreesia has set its FY 2026 guidance at EPS. Equities research analysts expect that Phreesia, Inc. will post -1.1 EPS for the current year.

Analyst Ratings Changes

PHR has been the topic of several recent analyst reports. DA Davidson upgraded shares of Phreesia to a "strong-buy" rating in a report on Monday. Wall Street Zen raised shares of Phreesia from a "hold" rating to a "buy" rating in a research report on Sunday, June 1st. JMP Securities upped their price objective on shares of Phreesia from $30.00 to $34.00 and gave the stock a "market outperform" rating in a research report on Monday. Stephens reaffirmed an "overweight" rating and issued a $32.00 price objective on shares of Phreesia in a research report on Wednesday, September 3rd. Finally, Truist Financial upped their price objective on shares of Phreesia from $35.00 to $36.00 and gave the stock a "buy" rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating and twelve have assigned a Buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $34.08.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.